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Abstract 
Chitosan and its derivative water soluble Chitosan oligosaccharide are used in a variety of 
applications in pharmaceutical preparations. In this study, 2 wild (ATCC 15729 and PAO1) 
and 2 mutant strains (PT121 and PT149) of P. aeruginosa are investigated for drug-drug in-
teractions in vitro. 10 antimicrobial agents (antibiotics) are combined with different degree of 
deacetylated Chitosans and Chitosan oligosaccharide. All the chitosans show synergistic ac-
tivity with sulfamethoxazole, a sulfonamide antimicrobial agent. It is interesting to observe 
that the MIC value for the MexEF-OprN overexpressing mutant strain of P. aeruginosa is 5 
fold higher than the other strains under investigation suggesting a possible role of this efflux 
pump in Sulfamethoxazole efflux. The findings suggest on the use of chitosans as enhancing 
agent in combination with antibiotics in pharmaceutical preparations. 
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Introduction 
Pseudomonas aeruginosa (P. aeruginosa) is a highly 
drug resistant and opportunistic pathogen. Due to the 
permeability barrier in the outer membrane it is 
naturally resistant to many antibiotics. Infections 
caused by P. aeruginosa are increasing both in hospi-
tals and in general community and it has been re-
ported as one of the principal causes of nosocomial 
pathogen, particularly among immuno-compromised 
patients (1). Concurrently, the extensive use of antim-
icrobial agents and the evolutionary antimicrobial 
resistance strategies of bacteria have resulted in the 
emergence of pan-drug resistant bacteria (2). The ef-
ficacy of many antibiotics for treatment of infections 
has become quite limited due to the development of 
resistance and the threat from antimicrobial-resistant 
organisms is accumulating and accelerating. (3). Also, 
the development of resistance to monotherapy is a 
common problem and dual antimicrobial coverage is 
often a necessity in Pseudomonas infections (4). At-
tempts have been made to deal with this problem by 
using combination therapy (5). Several studies have 
reported on the interaction of antimicrobial combina-
tions with multi-resistant planktonic strains of P. 
aeruginosa  (6, 7). It is also reported that complete 
eradication of the bacterial cells of Pseudomonas 
aeruginosa in biofilms is a therapeutic challenge and 
often results in recurrent and chronic infections (6, 7, 
8). Recently, Černohorska demonstrated the in vitro 
effect of 8 antibiotic combinations in P. aeruginosa 
biofilms, using biofilm susceptibility testing (8). Ear-
lier, Neu reviewed the data available on the combina-
tions of fluoroquinolones with other antimicrobial 
agents against several bacteria including P. aeruginosa 
(9). Also, Vancomycin in combination with cepha-
losporins and penicillins has been shown to synergis-




However, the threat from antimicrobial-resistant or-
ganisms is accumulating and accelerating (11). With 
the dearth of new antibiotics coming to the market-
place and the advance of MDR bacteria it is not diffi-
cult to see untreatable life-threatening bacterial infec-
tion becoming common (12). Moreover, it is difficult 
to identify strategies to prevent or delay the emer-
gence of resistance. Recently, Amyes et al., discussed 
on the principles for antibiotic usage to limit resis-
tance development (13). Thus, there is the need to find 
new ways to control P. aeruginosa and embark on the 
need for a continued search for new antimicrobial 
compounds.  
Chitin is a natural organic material which is the 
second most abundant to cellulose. It is biocompati-
ble, biodegradable and can be obtained from exo-
skeleton of animal sources particularly in crustacean, 
mollusks and insects and certain fungus. When chitin 
is deacetylated, a group of polymers collective known 
as chitosan are obtained. Various applications of chi-
tosan polymers ranging from water treatment, pulp 
and paper industry, to pharmaceutical, cosmetics, 
agriculture, food, membrane are proposed (14). The 
oral mean lethal dose for chitosans in mice is found to 
be in excess of 16 gm/day/kg of body weight, which 
is higher than that of sucrose (15). Antimicrobial ac-
tivity is one of the attractive features of chitosan. The 
antimicrobial activity of chitosan varies depending on 
their physical properties (degree of deacetylation 
(DD), and molecular weight), solvent, microorganism 
species and source. The antimicrobial activity is re-
ported to vary depending on the methods involved in 
preparation of different DD and molecular weight of 
chitosan (16, 17, 18, 19, 20, 21). Isolated reports are 
available on the use of combinations of antibiotics and 
chitosan and its derivates as antimicrobials. Decker et 
al. proposed on a synergistic chlorhexidine/chitosan 
combination for improved antiplaque strategies (22). 
Tobramycin is one of the antibiotics which is reported 
to show synergistic action with chitosan in planktonic 
culture of Pseudomonas aeruginosa (23). Bioadhesive 
and antimicrobial properties of chitosan and its de-
rivatives are effective in antimicrobial drug delivery 
control - release of Chlorhexidine and Nystat in oral 
preparation (24, 25, 26), release of ampicillin (27) and 
drug delivery system for Ofloxacin (28) in ophthalmic 
preparation. Tobramycin sulfate gastrointestinal re-
lease preparations (29) make chitosan attractive for 
combination with antimicrobial drugs.  
In this paper, the activity of Tetracycline, Sul-
famethoxazole, Trimethoprim, Clarithromycin, Po-
lymycinB, Ceftriazone, Chloramphenicol, Tobramy-
cin, Ofloxacin and Streptomycin are investigated 
when used in combination with different degree of 
deacetylated chitosans and its derivative Chitosan 
oligosaccharide against strains of P. aeruginosa.  
Material and methods 
Bacterial strain and inoculum preparation 
ATCC 15729, PAO1 wild type clinical strain, 
PT121 (PAO mexE::ΩHg i.e. a PAO1 derivative inac-
tivated by the insertion of a Ω Hg cassette in the cod-
ing region of MexE gene) and PT149 (PT149 
(MexEF-OprN overexpressor), strains of P. aeruginosa 
were used in this study. The overnight culture of 
bacteria strains was diluted with autoclaved ISO Sen-
sitest broth to get the final bacterial inoculum of 
approx. 7.5 x 105 CFU/ml in each well. The microplate 
was incubated at 37 degree Celsius for 20 to 24 hours 
in ambient air before interpretation as described by 
CLSI (clinical laboratory standardization Institute) 
guidelines. (30)  
Chitosans  
High molecular weight Crab chitin was pur-
chased from Bioline, Thailand. The crab chitin was 
deacetylated by Technique of Horowitz (31) and the 
degree of deacetylation was measured by FT-IR spec-
troscopy. Medium molecular weight chitosan (75 – 85 
% deacetylated) was purchased from Sigma- Aldrich. 
Medium Molecular weight chitosan (>90 % deacety-
lated) was further deacetylated by technique of 
Horowitz and the degree of deacetylation was meas-
ured by FT-IR spectroscopy. Low molecular weight 
chitosan (75-85% deacetylated chitosan) was pur-
chased from Sigma-Aldrich. Chitosan oligosaccharide 
lactate (>90% deacetylated) was purchased from 
Sigma–Aldrich. 
Antibiotics  
Antimicrobial powders of Clarithromycin (assay 
value >95% HPLC), Chloramphenicol, Ceftriaxone, 
Ofloxacin (assay value 99%), Polymycin B (assay 
value 60-70%), Sulfamethoxazole (assay value 99.9% 
HPLC), Streptomycin (assay value 98%), Tobramycin 
(assay value 98% TLC), Tetracycline (assay value 99%) 
and Trimethoprim (assay value 99% HPLC) were 
used. Stock antibiotic solutions were prepared and 
dilutions made according to the CLSI (Clinical Labo-
ratory Standardization Institute) method or manu-
facturer’s recommendations (30). The solvents and the 
diluents used for the preparation of stock solutions 
are listed in Supplementary Table 2.   
Determination of MIC 
The lowest concentration of the antimicrobial 
agent that inhibits the growth of the microorganism 
being tested as detected by lack of visual turbidity, 




test, is known as Minimum Inhibitory Concentration 
(MIC). The MICs for the antibiotics and chitosans 
under study were determined in duplicate by the mi-
crobroth dilution method in ISO-Sensitest Broth ac-
cording to CLSI (Clinical Laboratory Standardization 
Institute) (30). The antibiotic concentrations used in 
this experiment ranged from 0.007µg/ml to 
4049µg/ml depending on the MIC of the antibiotics. 
1024µg/ml to 4 µg/ml of chitosan solutions was used 
and 67536µg/ml to 128 µg/ml of Chitosan oligosac-
charide was used to determine the combinatorial ef-






Figure 1. A: MICs of different antibiotics against P. aeruginosa ATCC15279. B: MICs of different chitosans and chitosan 





Effect of acetate ion concentration on P. aerugi-
nosa 
Two sets of test were performed in the determi-
nation of MICs for chitosans. One with chitosans dis-
solved in acetate buffer and second set (control) with 
same volume of acetate buffer without chitosan. P. 
aeruginosa suspensions were incubated at 37 degree 
Celsius for 20 to 24 hours at ambient air. The effect of 
acetate ion on P. aeruginosa was determined by ana-
lyzing bacterial growth by spectrophotometric analy-
sis at 600nm (checking the turbidity when compared 
with negative control) (Figure 2). 
Checkerboard assay 
Checker board titration is one of the most fre-
quently used techniques to access drug interactions. 
Testing was performed utilizing 96 well microtiter 
plates. MICs were determined for each drug by broth 
microdilution according to standards of the CLSI 
(Clinical Laboratory Standardization Institute) (30). 
Each combination assay was performed at three times. 
Synergism by the checkerboard method was defined 
as an FIC index of ≤ 0.5, additive effect was defined as 
an FIC index of > 0.5 and ≤ 1, Indifference effect was 
defined as an FIC index of > 1 and ≤ 2 and antagonism 
effect was defined as an FIC index of > 4. Concentra-
tions within the FIC panel were such that the MIC of 
each antibiotic was in the middle of the range of con-
centrations tested.  
The FIC indices for all combinations were calcu-
lated using the formula below: 
1. The FIC for a drug in a given well is derived 
by dividing the drug concentration in the given well 
by the control MIC of the test organism to that drug. 
FICA = MICA combination / MICA alone 
FICB = MICB combination / MICB alone 
2. The FIC index for a well is the sum of the FICs 
for each of the drugs present in the well: 
FICindex = FICA+FICB 
Population Analysis 
Plate counting was performed to quantitate the 
log concentration of bacteria colony forming unit 
(CFUs) per milliliter, using the final concentration of 
the antibiotics and chitosans that showed synergism 
derived from checkerboard method (Figure 4). 
 
Figure 2: Antibacterial activity of acetate 
buffer showing acetate ions concentra-
tion verses OD at 600nm. 
 
Figure 3: The reduction in MIC of Sul-
famethoxazole (sulf) after combination 
with ¼ MIC of chitosan (8µg/ml) and ¼ 
MIC of Chitosan oligosaccharide (512 
µg/ml) against different strains of 
P.aeruginosa. Yellow is P aeruginosa 
ATCC15279; Blue is P aeruginosa PT121 ; 
Cyan is P aeruginosa PT149 and Green is P 





Figure 4: Population analysis of P. aeruginosa in combination of chitosans and Sulfamethoxazole. (1/4 MIC of chitosan/ 
Chitosan oligosaccharide and 1/8 MIC of Sulfamethoxazole) 
Results 
Antimicrobial activity of acetate buffer 
The antimicrobial activity of acetate buffer was 
investigated to evaluate the antimicrobial activity of 
chitosans which are only soluble in acetic acid. The 
antimicrobial activity of acetate buffer was observed 
at acetate ion concentration of 0.06% in control sets. It 
should be noted that at the concentration of 32µg/ml, 
MIC of chitosan for all P. aeruginosa strains, the con-
centration of acetate ion is less than 0.03%. Thus, the 
antimicrobial action of chitosans exceeded that of 
acetate buffer in the test (Figure 2). The antibacterial 
activity of the chitosan at culture media pH< 6 has 
earlier been performed (31, 32, 33). 
Anti-pseudomonal activity of different antibiotics 
The susceptibility range of the P. aeruginosa spe-
cies was evaluated using 10 antibiotics (Tetracycline, 
Sulfamethoxazole, Trimethoprim, Clarithromycin, 
PolymycinB, Ceftriazone, Chloramphenicol, Tobra-
mycin, Ofloxacin and Streptomycin) and 5 chitosans 
(HMW, MMW, De MMW, LMW and chitosan oligo-
saccharide). MIC values are shown in Figure 1A. MIC 
value is found to be lowest for Tobramycin 
(0.25µg/ml) and highest for Chloramphenicol 
(128µg/ml). It is observed that MIC for all the chito-
sans is 32 µg/ml except chitosan oligosaccharide 
which shows an MIC value of 4096 µg/ml. This shows 
that chitosan oligosaccharide is not an effective an-
timicrobial agent when compared with the other chi-
tosans under investigation (Figure 1B). 
Anti-pseudomonal activity of Chitosans and 
Chitosan oligosaccharide 
The antimicrobial activity of chitosans and Chi-
tosan oligosaccharide against P. aeruginosa strains are 
shown in Table 1. Antibacterial activity against P. 
aeruginosa starts at a concentration of 32µg/ml. The 
results show that all the five chitosan preparations 
had antibacterial activity against four different strains 
of  P. aeruginosa. Similarly, Chitosan oligosaccharide 
displayed the anti bacterial activity against all the four 
P. aeruginosa strains at a much higher concentration 
(4096µg/ml). 
Table 1: MICs of compounds under investigation for different strains of P.aeruginosa. HMW= High molecular weight 
chitosan; MMW = Medium molecular weight chitosan; MMW (de) = Deacetylated medium molecular weight chitosan ; 
LMW= Low molecular weight chitosan; and Chitosan_oligo = Chitosan oligosaccharide. 
Bacteria Strain  MIC of Sulfamethoxazole MIC of HMW  MIC of MMW MIC of MMW (de) MIC of LMW MIC of Chitosan_oligo
P. aeruginosa ATCC15279 64µg/ml 32µg/ml  32µg/ml  32µg/ml  32µg/ml  4096µg/ml 
P. aeruginosa PA01  128µg/ml 32µg/ml  32µg/ml  32µg/ml  32µg/ml  4096µg/ml 
P. aeruginosa PT121  128µg/ml 32µg/ml  32µg/ml  32µg/ml  32µg/ml  4096µg/ml 
P. aeruginosa PT149  2048µg/ml 32µg/ml  32µg/ml  32µg/ml  32µg/ml  4096µg/ml 





Checkerboard assay results 
In checkerboard assay, the combination of the 
above mentioned antibiotics and different chitosan 
preparations and Chitosan oligosaccharide show 
synergistic action with Sulfamethoxazole against P. 
aeruginosa  ATCC15729. 8µg/ml of four chitosan 
preparations and 512 µg/ml of Chitosan oligosaccha-
ride effectively combine with 8 µg/ml of Sulfameth-
oxazole (Fractional Inhibitory Concentration, FIC index 
= 0.375). The remaining combinations show additive 
effect in the checkerboard assay. (FIC index 0.5 – 1.0). 
The ΣFIC data are shown in the table 3. 
The identified synergistic combinations of Sul-
famethoxazole / chitosan and Sulfamethoxazole / 
Chitosan oligosaccharide were further investigated 
with three different clinical strains of P. aeruginosa 
PAO1 wild type, PT121 and PT149 strains (Please see 
materials and methods for details). Chitosan and 
Chitosan oligosaccharide were found to have syner-
gistic effect when combined with Sulfamethoxazole 
against all the three Pseudomonas strains. 8 µg/ml of 
four chitosan preparations synergistically combined 
with 32 µg/ml of Sulfamethoxazole (FIC index = 0.25) 
and 512 µg/ml of Chitosan oligosaccharide with 16 
µg/ml of Sulfamethoxazole against PAO1, PT121 and 
PT149 strain (FIC index = 0.375). (Table 2, Figure 3.). The 
results were also confirmed by population analysis for 
P. aeruginosa ATCC strain (Figure 4). 
 
Table 2: FIC index for different combination of Sulfamethoxazole with different chitosan preparations against four strains of 
P. aeruginosa. Sulf = Sulfamethoxazole. HMW= High molecular weight chitosan; MMW = Medium molecular weight chitosan; 
MMW (de) = Deacetylated medium molecular weight chitosan ; LMW= Low molecular weight chitosan; and Chitosan_oligo 
= Chitosan oligosaccharide. 








Sulf + HMW  0.375  0.25  0.25  0.25 
Sulf + MMW  0.375  0.25  0.25  0.25 
Sulf + MMW(de)  0.375  0.25  0.25  0.25 
Sulf + LMW  0.375  0.25  0.25  0.25 
Sulf + chitosan_ oligo  0.375  0.375  0.375  0.375 
 
Table 3. FIC values of different chitosans and different antibiotics. HMW= High molecular weight chitosan; MMW = Me-
dium molecular weight chitosan; MMW (de) = Deacetylated medium molecular weight chitosan ; LMW= Low molecular 
weight chitosan; and Chitosan_oligo = Chitosan oligosaccharide. 
Antimicrobial Agents  Oligo 
ΣFIC 
Remark LMW 
  ΣFIC 
Remark DeMMW 
  ΣFIC 
Remark MMW 
  ΣFIC 
Remark HMW 
  ΣFIC 
Remark 
Clarithomycin  0.75  Additive 0.75  Additive 0.625  Additive 0.75  Additive 0.75  Additive 
Ceftriazone  0.75  Additive 0.75  Additive 1  Additive 1  Additive 0.625  Additive 
Chloramphenicol  0.625  Additive 1  Additive 1  Additive 0.75  Additive 1  Additive 
Ofloxacin  0.75  Additive 1  Additive 1  Additive 1  Additive 1  Additive 
Polymycin  B  1  Additive 0.75  Additive 1  Additive 1  Additive 0.625  Additive 
Sulfamethoxazole  0.375  Synergy 0.375  Synergy 0.375  Synergy 0.375  Synergy 0.375  Synergy 
Streptomycin  0.75  Additive 1  Additive 1  Additive 1  Additive 1  Additive 
Tetracycline  0.75  Additive 0.625  Additive 0.75  Additive 1  Additive 0.75  Additive 
Tobramycin  1  Additive 0.75  Additive 1  Additive 0.75  Additive 1  Additive 




P. aeruginosa is an important bacterial pathogen 
most frequently responsible for nosocomial infections. 
It is often resistant to many antibiotics used in causa-
tive therapy. The efficacy of many antibiotics for 
treatment of severe infections has become quite lim-
ited due to the development of resistance. Improving 
the effectiveness and decreasing the toxicity of anti-
biotics are the two basic objectives in the development 
of novel antimicrobial agents. Utilization of combina-
tion therapy is one of the contemporary approaches 
for successful modulation of existent antibiotics (34).  
Many published data indicate that chitosan and 
its derivatives have certain in vitro antibacterial activ-
ity. Recently, Raafat et al., proposed that there might 
not be a single classical target that would explain 
chitosan’s antimicrobial action, and speculated that 
binding of chitosan to teichoic acids, coupled with a 
potential extraction of membrane lipids (predomi-
nantly lipoteichoic acid) results in a sequence of 
events, ultimately leading to bacterial death (35). Ear-




chitosan caused extensive cell surface alterations, 
bound to the outer membrane and caused the loss of 
the barrier function of the outer membrane (36). 
However, till date, its exact mode of action remains 
obscure. Nonetheless, it is clear that its diverse 
physical properties in combination with antimicrobial 
activities make it and its derivatives applicable in 
different function in pharmaceutical preparations. 
Our results reveal the importance of chitosan 
and its derivatives as they have strong antibacterial 
activity against resistant bacteria like P. aeruginosa. 
Furthermore, these chitosan derivatives are active 
against antibiotic resistant bacteria at very low con-
centration (32µg/ml). The MIC of Chitosan oligosac-
charide (2046µg/ml) is higher than that of other chi-
tosan preparations. This is in agreement with earlier 
report by Jeon et al. (23). It must be noted that the MIC 
concentrations are much below the toxicity level. It 
has been reported earlier in an in vivo study, that chi-
tosans have no evidence of toxicity (9) and the LD50 
of chitosan in mice is 16g/kg of body weight(25).  
When in combination with Sulfamethoxazole, 
sub MIC concentrations of chitosan (8µg/ml) and 
Chitosan oligosaccharide (512µg/ml) can effectively 
inhibit the growth of various Pseudomonas strains. 
The presence of antibacterial activity against P. 
aeruginosa ATCC15279 was seen at Sulfamethoxazole 
concentration as low as 8 fold (8 µg/ml) of its MIC. 
Antibacterial activity against three different clinical 
strains PAO1, PT121 and PT149, shows synergistic 
behavior suggesting that chitosan and Chitosan oli-
gosaccharide are promising compounds for combina-
tion antimicrobial therapy against drug resistant 
pseudomonal infections. 
In P. aeruginosa PT149, the MIC of Sulfameth-
oxazole was found to be 5 fold higher than the re-
maining strains suggesting that Sulfamethoxazole 
might be effluxed by the MexEF-OprN system, 
thereby reducing the effective concentration of the 
folic acid biosynthesis inhibitor. Thus, the reduction 
in drug accumulation is more apparent in the 
MexEF-OprN overexpressor. Although, Sulfameth-
oxazole has high MIC, chitosan and Chitosan oligo-
saccharide remain effective against this mutant strain 
either singly (MIC of 32 µg/ml and 4096 µg/ml re-
spectively) or in combination (8 µg/ml of chitosans 
lower the MIC of sulfamethoxazole to 512µg/ml and 
512µg/ml of Chitosan oligosaccharide lower the MIC 
of sulfamethoxazole to 256µg/ml). These finding 
provide a strong evidence that chitosans and Chitosan 
oligosaccharide are promising candidates for combi-
nation therapy against multi drug resistant P. aerugi-
nosa infections. 
From the results of FIC index , Chitosan oligosac-
charide proves to be a better combination for Sul-
famethoxazole against P. aeruginosa , as the FIC index 
are relatively lower than that of four different prepa-
rations of chitosan. 
These in vitro data still need to be validated by 
assessing the clinical performance of antibiotic com-
binations. These findings could also prove to be a 
promising alternative in the treatment of patients for 
whom existing antimicrobial treatment fails. Despite 
the lack of knowledge for the underlying mechanism 
of the synergistic effect of Sulfamethoxazole-chitosan 
and Sulfamethoxazole-Chitosan oligosaccharide 
combinations, the potential for use of such combina-
tions clinically is huge since it may be able to make 
some untreatable resistant infections treatable at cur-
rently recommended dosages that are often margin-
ally effective against resistant strains when used 
alone. These data encourage further studies with chi-
tin derivatives and other antimicrobial classes and in 
vivo animal experiments to validate these interesting 
findings before clinical tests can move forward. 
Supplementary Material 
Supplementary Table 1 
[http://www.biolsci.org/v05p0153s1.pdf] 
Supplementary Table 2 
[http://www.biolsci.org/v05p0153s2.pdf] 
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